Detalhe da pesquisa
1.
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
Blood
; 115(21): 4206-16, 2010 May 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-20299508
2.
Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.
Blood
; 112(13): 5161-70, 2008 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18820131
3.
Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.
Mol Cancer Ther
; 6(7): 1951-61, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17620426
4.
Discovery and characterization of novel mutant FLT3 kinase inhibitors.
Mol Cancer Ther
; 9(9): 2468-77, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20807780
5.
Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
Blood
; 111(7): 3723-34, 2008 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18184863
6.
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
Blood
; 109(5): 2112-20, 2007 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17068153
7.
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
Blood
; 110(13): 4417-26, 2007 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17761832
8.
Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Gastroenterology
; 131(6): 1734-42, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17087936